CD247 and neoplasm: In a preclinical study investigating CD19-directed CAR-NK cells, the addition of DAP10, a physiological adapter of NKG2D, resulted in enhanced anti-tumor potency compared with constructs using CD3ζ signals alone (4, 68, 69).